Drug Maker Concealed Collusive Activity From Investors, Shareholder Argues
NEW YORK — A pharmaceutical company and certain of its current and former executive officers misrepresented the company’s business and financial condition to investors and engaged in violations of federal antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article